Retisert intravitreal

Driot JY, Novack G, Rittenhouse K, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004 20(3) 269-270. 

Fluo- cinolone acetonide Retisert Intravitreal implant PVA-sihcone Uveitis In market... 

Retisert Fluocinolone acetonide Bausch Lomb Marketed product Uveitis Intravitreal implant... 

Intravitreal triamcinolone has been used to treat diffuse diabetic macular edema. Also, an intravitreal implant delivering fluocinolone acetonide (Retisert) is effective in the treatment of patients with noninfectious posterior uveitis who have failed to respond to conventional treatment. 

Another relatively recent development for the management of intermediate and/or posterior uveitis is the sustained-release intravitreal corticosteroid implant, for example, Retisert (fluocinolone acetonide 0.59 mg Bausch Lomb, Rochester, NY, USA). Retisert is indicated fc)r the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. An intravitreal dexamethasone implant is also currently luider investigation. 

Chronic Uveitis. IVTA has been used in several small series of patients with chronic CME due to chronic uveitis. Despite the long duration of edema, most patients demonstrated improvement in acuity lasting for 3 to 6 months, but others experienced a decline between 6 and 12 months after the initial injection, returning to the pretreatment acuity level. Anatomic improvement, demonstrated as reduced retinal thickening by optical coherence tomography, was likewise achieved by patients with CME that had been persistent for up to 11 years. Few of these patients had subsequent injections, so the ability of IVTA to maintain the initial improvement in acuity is unknown. An intravitreal implant device (Retisert, Bausch Lomb Incorporated, Tampa, EL, USA)... 

---